GLP-1 Starter · FormBlends network
Know what your first weeks on a GLP-1 will feel like before you start.
For week zero: who the labels say these medicines are for, what the first injection is like, what weeks 1 to 12 usually bring, and when to call a clinician.
- 0.25 mg
- Wegovy starting dose, held for the first four weeks
- The Wegovy starting dose, held four weeks so your stomach can adjust.
- 2.5 mg
- Zepbound starting dose; initiation only, not a maintenance dose
- The Zepbound starting dose. It is a warm-up, not a treatment dose.
- 6 weeks
- of week-by-week expectations, written before you start
- Week-by-week expectations written down so nothing surprises you.
Start here
Three ways in, depending on what you need right now
Interactive
Calculators
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
CalculatorLabel population checker
Do your BMI and conditions match the wording in the Wegovy, Zepbound, Ozempic or Mounjaro label?
CalculatorWeek-by-week planner
Pick a start date and a label schedule; get a dated calendar of titration weeks and what each one tends to bring.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Guides
Eating when you have no appetite
You'll get: On a GLP-1 the food problem is usually eating too little, not too much.
The food problem on a GLP-1 is usually too little: not enough protein or fluid, and meals that trigger nausea. What to eat first and what to avoid.
Guides
When to call a clinician: the symptoms the labels name
You'll get: This is the warning list from the patient medication guides, sorted by how fast to act.
The warning symptoms from the Wegovy and Zepbound Medication Guides, sorted by how fast to act, with the label warning each one belongs to. Print it and put it where you will find it on a bad day.
Guides
Common claims about GLP-1s, checked against the sources
You'll get: Ten common claims about GLP-1 medicines, each checked against a label, a trial or an FDA page.
Ten things people hear before starting a GLP-1, each checked against the labels, trials or an FDA page. Some false, some half true, two surprisingly true.
Start
What a GLP-1 medicine is, in plain words
You'll get: GLP-1 is a gut hormone your body releases after eating. It slows your stomach and tells your brain you are full.
Before the brand names and the dosing ladders: what GLP-1 stands for, what these injections copy in your body, why they change appetite, and which four products this site talks about.
Start
Who the labels say these medicines are for
You'll get: Wegovy and Zepbound labels describe adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
The exact population wording from the Wegovy, Zepbound, Ozempic and Mounjaro labels, what it leaves out, and why matching it is not being eligible.
Live updates
What changed since this site was written
Sources checked October 23, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching starting and staying on semaglutide or tirzepatide (389 in total).
- Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide
Diabet Med · October 19, 2026 · PubMed 42897718
- Real-World Semaglutide Initiation Behaviours in the United States: Impact on Early Treatment Discontinuation and on 1-Year Persistence
Diabetes Obes Metab · October 19, 2026 · PubMed 42897121
- Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort
Endocr Pract · October 15, 2026 · PubMed 42880590
- Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
Intern Med · October 15, 2026 · PubMed 42875211
- Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity
Diabetes Obes Metab · October 14, 2026 · PubMed 42875827
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
18 pages across 3 sections, each sourced to a label, a trial or a dated manufacturer page.
Start
You'll get: 7 sourced pages, each with a plain-English opener
Before the brand names and the dosing ladders: what GLP-1 stands for, what these injections copy in your...
Weeks
You'll get: 6 sourced pages, each with a plain-English opener
Where the needle goes, what each device does, how long the shot takes, what you feel in the first three...
Guides
You'll get: 5 sourced pages, each with a plain-English opener
The food problem on a GLP-1 is usually too little: not enough protein or fluid, and meals that trigger...
Read in this order
Start with what the medicines are and who the labels say they are for. Then read how a prescriber decides and the brand versus compounded page, because those two decide most of what follows. The week-by-week pages are for after you have a start date. The guides on food, fluids and warning symptoms are worth reading before the first injection, not after.
What this site will not do
It will not tell you that you qualify, pick a medicine, set a dose, or interpret your symptoms. The label population checker only reports whether your numbers match the wording in the Wegovy, Zepbound, Ozempic or Mounjaro label; a prescriber decides eligibility. The week-by-week planner lays out label titration dates and what the labels and trials say about each stretch; it never chooses a dose. Compounded GLP-1s are not FDA approved and are not interchangeable with brand products, and this site says so wherever it matters.